Abbott announced today that it completed its acquisition of Cardiovascular Systems. In February, Abbott announced its agreement to acquire the atherectomy technology developer. Abbott agreed to pay $20 per common share of Cardiovascular Systems, leading to a total expected equity value of about $890 million. Cardiovascular Systems develops the Diamondback 360 system for atherectomy in […]
Cardiovascular Systems
Cardiovascular Systems completes enrollment in Eclipse clinical trial
Cardiovascular Systems this week announced it completed enrollment in its Eclipse coronary trial. The company enrolled 2,000 patients with severely calcified coronary lesions in the prospective, multicenter, randomized clinical trial. Half of the participants received orbital atherectomy prior to drug-eluting stent implantation, and the other hand received conventional angioplasty, including specialty balloons and DES implantation. […]
Abbott to acquire Cardiovascular Systems for $890M
Abbott (NYSE: ABT) is making an important play to expand its cardiovascular device portfolio, announcing that it plans to acquire Cardiovascular Systems (Nasdaq: CSII). The two companies’ agreement, announced after market close yesterday, would provide $20 per common share for Cardiovascular Systems stockholders. The total expected equity value of the deal would be roughly $890 […]
Cardiovascular Systems posts mixed-bag Q1 results
Cardiovascular Systems (NSDQ:CSII) today posted first-quarter results that beat the revenue consensus on Wall Street but missed earnings estimates. The St. Paul, Minnesota-based heart device maker reported losses of $10.6 million, or -27¢ per share, on sales of $59.67 million for the three months ended September 30 for a sales gain of 2.23% compared with Q1 […]
Cardiovascular Systems launches 2.00 Max Crown for peripheral orbital atherectomy systems
Cardiovascular Systems (Nasdaq:CSII) announced today that it fully launched its 2.00 Max Crown for peripheral orbital atherectomy systems. St. Paul, Minnesota–based Cardiovascular Systems built the 2.00 Max Crown on its Diamondback 360 orbital atherectomy platform. It features an increased 70-micron, diamond-coated crown. According to a news release, the crown creates more efficient engagement in mixed […]
Cardiovascular Systems misses Wall Street estimates in Q4, anticipates revenue growth in FY 2023
Cardiovascular Systems (NSDQ:CSII) today posted fourth-quarter results that missed the overall consensus on Wall Street. The St. Paul, Minnesota-based heart device company reported losses of $9.69 million, or -25¢ per share, on sales of $62.5 million for the three months ended June 30, for a bottom-line loss of 83.3% on sales loss of 11.96% compared with Q4 […]
The biggest medtech personnel moves so far in 2022
In the ever-changing world of medtech, those who are leading the companies are bound to move around a bit. At the end of last year, we compiled a list of medtech’s biggest personnel changes in 2021. So far in 2022, we’ve already seen a slew of major moves involving some of the space’s most powerful […]
Cardiovascular Systems reports 11% sales loss in Q3 results
Cardiovascular Systems (NSDQ:CSII) this week posted third-quarter results that beat the earnings consensus on Wall Street but missed revenue estimates. The St. Paul, Minnesota-based heart device company reported losses of $9.7 million, or -25¢ per share, on sales of $56.2 million for the three months ended March 31, for a sales loss of -11.15% compared […]
Cardiovascular Systems treats first patients using Propel pVAD
Cardiovascular Systems (Nasdaq:CSII) today announced the first in-human procedures using its Propel percutaneous ventricular assist device. The first patients were treated at Piedmont Heart Institute and Cardiovascular Services in Tbilisi, Georgia by Dr. David Kandzari. The St. Paul, Minnesota-based company reported that Propel performed as intended and provided uninterrupted hemodynamic support leading to successful revascularization. […]
Former Cardiovascular Systems chief medical officer joins Big Sky Biomedical incubator
Dr. Ryan Egeland — who served as Cardiovascular Systems’ chief medical officer until earlier this month — has joined the Big Sky Biomedical incubator as a managing director. “Big Sky Biomedical was founded to enhance early-stage innovation and development in some of the fastest-growing segments of healthcare, including neurovascular, structural heart, and regenerative medicine,” Egeland […]
Cardiovascular Systems appoints chief medical officer
Cardiovascular Systems (NSDQ:CSII) announced today that it appointed Dr. Jeffery W. Chambers as its chief medical officer. St. Paul, Minnesota-based Cardiovascular Systems said in a news release that Chambers served as the primary investigator for the Orbit II study — the pivotal trial supporting premarket approval for the use of orbital atherectomy in coronary arteries. […]